Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Patients may be eligible for this study if they:~* Are at least 13 years old (need consent of parent or guardian if under 18).~* Are HIV-positive.~* Are in the 2nd or 3rd trimester (14 to 34 weeks pregnant) and are pregnant with one or two children.~* Have a normal ultrasound exam.~Exclusion Criteria~Patients will not be eligible for this study if they:~* Cannot take ZDV or 3TC.~* Have an active opportunistic (HIV-associated) or bacterial infection, or a severe medical condition.~* Have severe diarrhea.~* Are at risk for premature birth or pregnancy complications.~* Have a family history of phenylketonuria (PKU).~* Plan to breast-feed.~* Abuse alcohol or drugs.~* Cannot visit the same clinic for the duration of the study.~* Have taken certain anti-HIV drugs.

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).